comparemela.com

Latest Breaking News On - Cardiology scientific session - Page 12 : comparemela.com

Insomnia, sleep deprivation linked to increased risk for MI

NEW ORLEANS — Insomnia was associated with increased risk for MI, especially among older adults and women, according to a meta-analysis presented at the American College of Cardiology Scientific Session.“There have been studies that show that sleep deprivation leads to elevated cortisol which in turn accelerates atherosclerosis, contributing to coronary artery disease and subsequent

Self-expanding TAVR system shows durable benefits in low-risk patients at 3 years

NEW ORLEANS — At 3 years, patients with severe aortic stenosis at low surgical risk who had transcatheter aortic valve replacement with a self-expanding valve continued to have lower risk for death or stroke than those who had surgical AVR. In the main results of the Evolut Low Risk Trial, risk for all-cause mortality or disabling stroke at 2 years was numerically lower and noninferior in

Study questions prognostic value of myocardial viability in patient selection for PCI

NEW ORLEANS — PCI may not improve survival or left ventricular recovery among patients with ischemic cardiomyopathy compared with optimal medical therapy alone, regardless of baseline myocardial viability, a speaker reported. In addition, scar burden, not abundance of dysfunctional-yet-viable segments, was prognostic of LV recovery, independent of baseline LV ejection fraction or CAD

Tailored EHR alert increases prescribing for recommended heart failure drug

NEW ORLEANS — An automated, patient-specific, electronic health record-embedded tool was associated with increased prescriptions of mineralocorticoid receptor antagonists for patients with HF, the BETTER CARE-HF study showed. Researchers conducted a three-arm, pragmatic, cluster-randomized trial to determine the effectiveness on increasing mineralocorticoid receptor antagonist (MRA)

Bempedoic acid an effective alternative for statin-intolerant patients: CLEAR Outcomes

NEW ORLEANS — In the CLEAR Outcomes trial, bempedoic acid reduced risk for major CV events by 13% compared with placebo, including a 23% lower risk for MI, among adults with a history of CVD or at high risk deemed statin intolerant.Bempedoic acid (Nexletol, Esperion Therapeutics) was FDA approved in 2020 for lowering LDL, but the effects of the drug on CV outcomes have not been assessed,

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.